# MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

> **NCT00284921** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- De Novo Kidney Transplant

## Interventions

- **DRUG:** Enteric-coated Mycophenolate sodium (EC-MPS)

## Key facts

- **NCT ID:** NCT00284921
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04
- **Primary completion:** 2006-08
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284921, "MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00284921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*